Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ticagrelor 90 mg in Healthy Thai Volunteers
NCT06233266Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by Bio-innova. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 48 hours, Maximal measured plasma concentration at 48 hours and 1 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06233266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233266.